Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Keros Therapeutics (KROS)
NASDAQ:KROS
Holding KROS?
Track your performance easily
See the Price Targets and Ratings of:
KROS Analyst Ratings
Moderate Buy
11 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
KROS Stock 12 Month Forecast
Average Price Target
$53.33
▲(213.15% Upside)
| Highest Price Target$111.00 | Average Price Target$53.33 | Lowest Price Target$23.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Oppenheimer
Assigned
12/16/24
Piper Sandler
Assigned
12/16/24
Guggenheim
Downgraded
12/15/24
H.C. Wainwright
Reiterated
12/13/24
Truist Financial
Assigned
12/13/24
Scotiabank
Reiterated
12/13/24
Jefferies
Reiterated
12/13/24
Leerink Partners
Reiterated
12/12/24
BTIG
Downgraded
12/12/24
Bank of America Securities
Reiterated
12/12/24
Wells Fargo
$111
Buy
551.79%
Upside
Assigned
12/12/24
Wells Fargo Sticks to Its Buy Rating for Keros Therapeutics (KROS)
TD Cowen
―
Hold
―
Downgraded
12/12/24
TD Cowen downgrades Keros Therapeutics (KROS) to a Hold
William Blair
―
Hold
―
Downgraded
12/12/24
Keros Therapeutics downgraded to Market Perform from Outperform at William BlairKeros Therapeutics downgraded to Market Perform from Outperform at William Blair
Wedbush
$84
Buy
393.25%
Upside
Assigned
12/12/24
Positive Clinical Updates and Promising Therapeutic Potential for Elritercept in MDS and MF: A Strong Case for Continued Development
Cantor Fitzgerald
―
Buy
―
Initiated
10/24/24
Keros Therapeutics initiated with an Overweight at Cantor FitzgeraldKeros Therapeutics initiated with an Overweight at Cantor Fitzgerald
Best Analysts Covering Keros Therapeutics
Which Analyst Should I Follow If I Want to Buy KROS and Sell After:
1 Month
xxx
Success Rate
13/21 ratings generated profit
Average Return
+4.44%
assigned a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.90% of your transactions generating a profit, with an average return of +4.44% per trade.
3 Months
xxx
Success Rate
11/21 ratings generated profit
Average Return
+21.90%
assigned a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 52.38% of your transactions generating a profit, with an average return of +21.90% per trade.
1 Year
Success Rate
10/21 ratings generated profit
Average Return
+5.21%
assigned a buy rating 5 days ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +5.21% per trade.
2 Years
xxx
Success Rate
5/21 ratings generated profit
Average Return
-30.55%
assigned a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 23.81% of your transactions generating a profit, with an average return of -30.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
KROS Analyst Recommendation Trends
Rating
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
11
11
5
5
15
Buy
7
7
7
13
20
Hold
0
0
0
0
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
18
12
18
38
Each month's total comprises the sum of three months' worth of ratings.
KROS Financial Forecast
KROS Stock Forecast FAQ
What is KROS’s average 12-month price target, according to analysts?
Based on analyst ratings, Keros Therapeutics’s 12-month average price target is $53.33.
What is KROS’s upside potential, based on the analysts’ average price target?
Keros Therapeutics has 213.15% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KROS a Buy, Sell or Hold?
Keros Therapeutics has a consensus rating of Moderate Buy which is based on 11 buy ratings, 4 hold ratings and 0 sell ratings.
What is Keros Therapeutics’s price target?
The average price target for Keros Therapeutics is $53.33. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $111.00 ,the lowest forecast is $23.00. The average price target represents 213.15% Increase from the current price of $17.03.
The highest analyst price target is $111.00 ,the lowest forecast is $23.00. The average price target represents 213.15% Increase from the current price of $17.03.
What do analysts say about Keros Therapeutics?
Keros Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of KROS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.